Health and Fitness Health and Fitness
Thu, November 4, 2010
[ Thu, Nov 04th 2010 ] - Market Wire
RehabCare to Present at the Stephens Fall Investor Conference 2010
[ Thu, Nov 04th 2010 ] - Market Wire
Alkermes Reports Second Quarter Fiscal 2011 Financial Results
[ Thu, Nov 04th 2010 ] - Market Wire
Obagi Medical Products' Third Quarter 2010 Net Sales Rise 12 Percent
[ Thu, Nov 04th 2010 ] - Market Wire
Targacept Reports Third Quarter 2010 Financial Results
[ Thu, Nov 04th 2010 ] - Market Wire
Exelixis Announces Third Quarter 2010 Financial Results
[ Thu, Nov 04th 2010 ] - Market Wire
Emergent BioSolutions Reports Financial Results for Third Quarter and First Nine Months of 2010
[ Thu, Nov 04th 2010 ] - Market Wire
Chesley Files Class Action Against DePuy Orthopaedics
[ Thu, Nov 04th 2010 ] - Market Wire
Nasdaq Panel Grants American Learning Corporationa?s Request for Continued Listing
[ Thu, Nov 04th 2010 ] - Market Wire
El Senado de California proclama la semana del 7 .. 3 de noviembre como Semana Educativa sobre la CKD
[ Thu, Nov 04th 2010 ] - Market Wire
Medisafe 1 Technologies to Present Syringe Locking-Device Technology at HealthAchieve Conference
[ Thu, Nov 04th 2010 ] - Market Wire
Chemed Corporation to Present at the 2010 Annual Credit Suisse Healthcare Conference
[ Thu, Nov 04th 2010 ] - Market Wire
Medtronic Marks Bladder Health Awareness Month with National Womena?s Health Campaign
Wed, November 3, 2010
[ Wed, Nov 03rd 2010 ] - Market Wire
Kahn Swick & Foti, LLC and Former Louisiana State .. stors With Large Financial Interests (Over $100,0
[ Wed, Nov 03rd 2010 ] - Market Wire
Sanofi Pasteur's Dengue Vaccine in Final Stage of Clinical Development
[ Wed, Nov 03rd 2010 ] - Market Wire
La vacuna contra el dengue de Sanofi Pasteur est en fase final de desarrollo clnico
[ Wed, Nov 03rd 2010 ] - Market Wire
Alnylam Pharmaceuticals Reports Third Quarter 2010 Financial Results
[ Wed, Nov 03rd 2010 ] - Market Wire
SurModics and Edge Therapeutics Collaborate on De .. lopment of Sustained-Release Neurological Product
[ Wed, Nov 03rd 2010 ] - Market Wire
Teleflex to Present at the Credit Suisse 2010 Healthcare Conference
[ Wed, Nov 03rd 2010 ] - Market Wire
Pfizer Inc., MasterCard Inc., Capital One, Delta Air Lines and Visa
[ Wed, Nov 03rd 2010 ] - Market Wire
Eugene Melnyk Delivers Notice of Appeal in OSC Matter
[ Wed, Nov 03rd 2010 ] - Market Wire
Community Health Systems to Participate in Credit Suisse 2010 Healthcare Conference
[ Wed, Nov 03rd 2010 ] - Market Wire
Bio-Path Holdings Awarded Grant from the U.S. Gov .. Qualifying Therapeutic Discovery Project Program
[ Wed, Nov 03rd 2010 ] - Market Wire
Health Net Federal Services Awarded Department of Veterans Affairs Rural Mental Health Contract
[ Wed, Nov 03rd 2010 ] - Market Wire
Enzon Pharmaceuticals Awarded $1.2 Million in Grants under QTDP Program
[ Wed, Nov 03rd 2010 ] - Market Wire
Somaxon Pharmaceuticals Awarded Grant for Silenor .. Qualifying Therapeutic Discovery Project Program
[ Wed, Nov 03rd 2010 ] - Market Wire
Fibrocell Science, Inc. Establishes Joint Venture to Market Its Technology Platform in Asia
[ Wed, Nov 03rd 2010 ] - Market Wire
Viread® para hepatitis B mantiene la supresin an .. de resistencia durante cuatro aos de tratamiento
[ Wed, Nov 03rd 2010 ] - Market Wire
GTx Awarded $1.2 Million in Grants for Qualifying Therapeutic Discovery Projects
[ Wed, Nov 03rd 2010 ] - Market Wire
AVEO Pharmaceuticalsa? Tivozanib Recognized as On .. ndhovera?s 2011 Top 10 Oncology Projects to Watch
[ Wed, Nov 03rd 2010 ] - Market Wire
Emergent BioSolutions Receives Loan Repayment from Protein Sciences Corporation

Emergent BioSolutions Receives Loan Repayment from Protein Sciences Corporation


Published on 2010-11-03 10:15:37 - Market Wire
  Print publication without navigation


ROCKVILLE, Md.--([ BUSINESS WIRE ])--Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has received repayment of the loan it extended to Protein Sciences Corporation in 2008. The total payment of $11.5 million includes full repayment of the original $10 million in principal plus $1.5 million in accrued interest. In addition, the parties signed a mutual settlement and release agreement that dismisses all litigation between both parties.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a global biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the bodya™s immune system to prevent or treat disease. Emergenta™s marketed and investigational products target infectious diseases, oncology, and autoimmune disorders. Additional information about the company may be found at [ www.emergentbiosolutions.com ].

Contributing Sources